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ABSTRACT
Background: The Lung, hEart, sociAl, boDy (LEAD) Study (ClinicalTrials.gov; NCT01727518; http:==clinicaltrials.gov) is a
longitudinal, observational, population-based Austrian cohort that aims to investigate the relationship between genetic,
environmental, social, developmental and ageing factors influencing respiratory health and comorbidities through life. The
general working hypothesis of LEAD is the interaction of these genetic, environmental and socioeconomic factors influences
lung development and ageing, the risk of occurrence of several non-communicable diseases (respiratory, cardiovascular,
metabolic and neurologic), as well as their phenotypic (ie, clinical) presentation.
Methods: LEAD invited from 2011–2016 a random sample (stratified by age, gender, residential area) of Vienna inhabitants
(urban cohort) and all the inhabitants of six villages from Lower Austria (rural cohort). Participants will be followed-up every
four years. A number of investigations and measurements were obtained in each of the four domains of the study (Lung, hEart,
sociAl, boDy) including data to screen for lung, cardiovascular and metabolic diseases, osteoporosis, and cognitive function.
Blood and urine samples are stored in a biobank for future investigations.
Results: A total of 11.423 males (47.6%) and females (52.4%), aged 6–80 years have been included in the cohort. Compared to
governmental statistics, the external validity of LEAD with respect to age, gender, citizenship, and smoking status was high.
Conclusions: In conclusion, the LEAD cohort has been established following high quality standards; it is representative of the
Austrian population and offers a platform to understand lung development and ageing as a key mechanism of human health both
in early and late adulthood.
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INTRODUCTION
Chronic respiratory diseases, such as chronic obstructive
pulmonary disease (COPD) and asthma, are among the most
prevalent, severe and costly human diseases. COPD currently is
the 4th cause of death worldwide and it is expected to be the 3rd
in a decade.1 It affects about 10% of the adult population in
European countries. However, estimates in Austria almost triple
that figure.2,3 Tobacco smoking is the main risk factor for COPD
in developed countries but recent epidemiological studies indicate
that about a quarter of individuals with chronic airflow limitation
are never-smokers, and that early life events can also contribute to
its pathogenesis.4 The influence of other environmental exposures
either at work or at home, in urban and rural populations, is
unclear.5 Likewise, asthma is the most prevalent chronic disease in
childhood and affects about 5% of the population (children and
adults).6 It is estimated that there are 300 million asthma patients
worldwide.7
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Recently, attention has focused on lung developmental issues
during pregnancy, infancy, and adolescence as important drivers
of respiratory diseases later in life.8 Both genetic9 and environ-
mental factors, such as active10 and passive smoking,11 environ-
mental pollution,12 recurrent bronchopulmonary infections,13
socioeconomic status,14 occupation, and diet, can alter normal
lung. Low birth-weight is associated with lower lung function
later in life.15,16 Yet, the potential elements and pathogenic
mechanisms that control and influence lung development are not
well established.13,17,18 The Framingham cohort study, among
others, has shown that suboptimal lung function is the best
predictor of respiratory and, of note, cardiovascular health during
adulthood,19 but the relationship between respiratory health and
other health conditions is unclear.20
Non-communicable diseases (NCDs) are the major global
health problem of the XXI century.21 NCD’s are caused by
complex gene-environment interactions across the lifespan, from
fetus to old age22,23 and include, among others, chronic respiratory
diseases, cardiovascular diseases, metabolic diseases, osteopo-
rosis, and neuropsychiatric diseases. NCDs often coexist in the
same patient.24 For instance, cardiovascular diseases, skeletal
muscle dysfunction, osteoporosis, metabolic syndrome, and
depression are highly prevalent in patients with COPD25 and con-
tribute significantly to limit their quality of life and prognosis.26–30
Asthma is also associated with increased prevalence of
comorbidities, albeit they frequently remain undiagnosed.31
The LEAD (Lung, hEart, sociAl, boDy) study (ClinicalTrials.
gov; NCT01727518; http:==clinicaltrials.gov) is a longitudinal,
observational, population-based cohort that aims to investigate the
relationship between genetic, environmental, developmental, and
ageing factors influencing respiratory health and comorbidities
through life. The general working hypothesis of LEAD is that
the interaction of gene-environmental and socioeconomic factors
influences lung development, the risk of occurrence of several
major respiratory and cardiovascular diseases and other NCD’s, as
well as their phenotypic (ie, clinical) presentation. Accordingly,
the general goal of LEAD is to provide valid scientific information
that contributes to better understand how genetic, environmental
and socioeconomic factors influence: (1) the normal and
pathologic lung growth, development and ageing (ie, the natural
history of lung function in normal and pathological conditions);
(2) the risk of development of major NCD’s like COPD, asthma,
cardiovascular diseases, metabolic diseases (as diabetes and
metabolic syndrome), osteoporosis, and neuropsychiatric diseases
(mental disorders including anxiety, depression and impaired
cognitive function); and, (3) the phenotypic heterogeneity and
complex of chronic respiratory diseases, COPD in particular, and
their relation with coexisting comorbidities. Within this general
framework, different specific projects of LEAD will develop their
own working hypothesis and specific goals in four domains (Lung,
hEart, sociAl, boDy). Here, we describe in detail the methodology
used and the external validity (ie, representativeness of the general
Austrian population) of LEAD.
METHODS
Ethics
The local Ethics committee of Vienna approved the study
(protocol number: EK-11-117-0711). Participants signed in-
formed consent; those for children under the age of 18 had to
be signed by their parents=legal representative.
Study design
LEAD (ClinicalTrials.gov; NCT01727518; http:==clinicaltrials.
gov) is a longitudinal, observational, population based cohort
study with stratified samples from Vienna (urban population) and
Lower Austria (rural population). Recruitment and first study
visit started in February 2012 and finished in September 2016. A
flow chart with numbers for initial recruitment, inclusion, and
main measurements is presented as Figure 1. In total, 11,423
male and female, aged 6–80 years participated and completed the
first visit, including main measurements as described in detail in
Table 1.
LEAD is directed by a Steering Committee, consisting of four
Austrian academic clinical physicians (Marie-Kathrin Breyer,
Robab Breyer-Kohansal, Sylvia Hartl, and Otto Burghuber).
An international advisory board of five international respiratory
experts (Alvar Agusti, Torben Sigsgaard, Michael Studnicka,
Claus Vogelmeier, and Emiel Wouters) was convened. All of
them discussed and agreed on the design of the study and
interpretation of the results and have full access to the LEAD
database.
Recruitment strategy
For the urban cohort, we used the national inhabitants’ register
to invite a randomized stratified sample (by age, gender, and
residential area) of Vienna inhabitants to participate. For the
rural cohort, due to the low total inhabitants’ number, every
registered inhabitant of six villages from Lower Austria was
invited. Selected urban and rural participants received a
personalized invitation letter. If the selected person did not
respond within 30 days, a maximum of two other personalized
invitation letter were sent at regular intervals. Due to the national
Austrian data protection act, we did not have access to
information on other contact details (eg, telephone number).
Exclusion criteria were pregnancy, current breast feeding, or
poor German language skills. Individuals participated voluntarily
without any reimbursement.
Follow-up
Every participant will be assessed every 4 years from individual’s
first study visit with all measurements described in detail in
Table 1. In case of loss to follow-up, the national inhabitants’
register provides information on emigration or death. As the study
is designed longitudinally, the numbers of loss to follow-up will
be substituted with re-recruitment (by age, gender, and residential
area).
Measurements
All measurements were performed at the LEAD study centre of
the Ludwig Boltzmann Institute for COPD and Respiratory
Epidemiology at the Otto Wagner Hospital in Vienna, Austria.
Table 1 details all measurements obtained in each participant
according to her=his age. To screen for major NCD’s, a number
of investigations and measurements were obtained in each of
the four domains of the study (Lung, hEart, sociAl, boDy), as
detailed in Table 1 and only briefly discussed below. Blood and
urine samples were analyzed for routine clinical measurements
and stored in a biobank for future investigations.
Lung domain
Lung function measures included pre- and post-bronchodilation
spirometry and static lung volumes, effort-independent measures
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of oscillatory resistance, and carbon monoxide lung diffusing
capacity (DLCO). Measurements were obtained according to
international recommendations32 and reference values used
correspond to those of the Global Lung Function Initiative
(GLI).33 Skin Prick Tests for major allergens (see Table 1) were
obtained in every participant. Smoking history and exposure to
environmental tobacco smoke (ETS) was recorded. History of
respiratory diseases, allergy, and related medication from the
individual and spouses, as well as respiratory symptoms, were
collected using a questionnaire.
To investigate COPD and asthma in more detail, a subgroup
of participants was invited for additional measurements. Every
participant with a positive Skin Prick Test or doctor-diagnosed
asthma or allergy or elevated blood eosinophils was re-invited for
bronchial provocation and fractional exhaled nitric oxide (FeNO)
testing and an Asthma Control TestTM (subgroup 1). Every partici-
pant with an forced expiratory volume in the first second (FEV1)=
forced vital capacity (FVC) below Lower Limits of Normal by
GLI33 or below 70% was re-invited for a 6-minute walking test,
COPD and health related questionnaires, and Alpha 1-Antitrypsin
testing (subgroup 2). Details are explained in Figure 2.
HEart domain
Cardiovascular measurements included arterial blood pressure,
automated electrocardiogram, carotid femoral-pulse wave veloc-
ity, and blood pressure measurements at both the upper and the
lower extremities. History of cardiovascular diseases and events
and related medication from the individual and spouses were
collected using a questionnaire.
SociAl domain
To evaluate environmental risk factors for chronic respiratory
diseases, data from the Environment Agency Austria of seventeen
monitoring units was used to determine the average concen-
trations of particulate matter 10 (PM10) and Nitrogen oxide
(NOX) within 10m3 of every participant’s home and workplace.
A map showing the monitoring units in Vienna and the average
exposure on PM10 and NOx in the year 2015 is presented as
Figure 3. Socioeconomic status (income, education, occupation)
of the individual or parents=legal representative (if underage) was
collected. To study the presence of neuropsychiatric diseases
such as anxiety, depression, and impaired cognitive function, we
used standardized questionnaires and test modules (as detailed in
Table 1).
BoDy domain
To determine the presence of diabetes and metabolic syndrome,
we measured fasting glucose in peripheral venous blood, glycated
hemoglobin (HbA1c), body mass index, waist circumference,
fat mass=fat free mass, blood lipid profiles, and blood pressure.
The presence of osteoporosis was determined using dual-energy
X-ray absorptiometry. History of diabetes, metabolic syndrome,
and osteoporosis and related medication from the individual and































Figure 1. Flow chart of study population including invitation, inclusion, and main measurements.
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Quality control
To guarantee optimal quality of the whole process, the following
measures were implemented from scratch: (1) all clinical
examiners (medical students) were trained by senior staff
(medical doctors=lung function technicians) and were supervised
regularly; (2) standardized protocols were predetermined for
every single measurement, based on international standards;
(3) all questionnaires are interview based; (4) a web-tool was
designed (www.linkthat.eu) that included control mechanism,
which permits inconclusive data entry (eg, typing errors,
implausible numbers), and all data from study equipment is
uploaded directly by data transfer to avoid manual data input
Table 1. Measurements and methods used in LEAD
Measurement Description Equipment
Demographics and Anthropometrics
Age, Gender, Height, Weight, waist circumference Questionnaire
Socioeconomic status (Income, education, occupation, religion, migration) Questionnaire
Community (Urban=Rural)
height, weight, waist circumference
Pregnancy test (female, 12–60
years)
Human chorionic gonadotropin (hCG) in urine Alere HCG R-20™
Birth and infancy data
Birth-weight Questionnaire
Prematurity Questionnaire
Diseases and co-morbidities in family (non-communicable diseases, Allergy=Atopy) Questionnaire




Individual smoking (Pack years, age start=quit smoking) Questionnaire
Environmental tobacco smoke (ETS): parents, grandparents, friends
Environmental tobacco smoke (ETS): at home, school, work
Data from the Environment Agency Austria of 17 monitoring units have been used in a calculated
emission=combustion model for average concentrations of particulate matter 10 (PM10) and
Nitrogen oxide (NOX) within 10m3 of every participant’s home and work place address
Calculation model of the Institute for Internal Combustion Engines and
Thermodynamics, Graz University of Technology, Austria and the
Municipal Department for Environmental Protection of Vienna48
Allergies
Skin-prick test49 Skin prick with allergens for ash tree, tree pollens mix (hazel, alder, birch), 5-grass-mix, mugwort,
ragweed, ribwort, mites mix, Alternaria, dog and cat dander
ALK-Abelló Allergie-Service G.m.b.H.
Domain Lung




Ever diagnoses of Asthma, COPD, other respiratory diseases Questionnaire
Spirometry Pre- and post-bronchodilation Carl Rainer GmbH, Austria™
Body plethysmography Pre- and post-bronchodilation Carl Rainer GmbH, Austria™
Oscillatory resistance from visit 2 Post bronchodilation Resmon™ Pro Forced Oscillation Technique
Diffusing capacity, DLCO from
visit 2
Single-breath post bronchodilation Carl Rainer GmbH, Austria™
Domain hEart
Ever diagnoses of angina pectoris, stroke, congestive heart failure, arrhythmia, other
cardiovascular diseases
Questionnaire
Arterial blood pressure50 By Sphygmomanometer Hokanson S12™ and DS400 Aneroid™
12-lead electrocardiogram51 Cardiac infarction injury score Cardiosoft, GE Healthcare®, Austria
Non-invasive applanation
tonometry52
Arterial stiffness by carotid femoral-pulse wave velocity (PWV) and Augmentation time Index by
pulse wave analysis (PWA)
Spygmocor, Novomed®, Austria
Ankle-brachial index53 By sphygmomanometer and Doppler probe at upper and the lower extremities ELCAT® GmbH, Germany
Domain SociAl
LEAD questionnaire children (age 6–10 years) Composed of:
1. National Health and Nutrition Examination Survey54
2. ISAAC. The International Study of Asthma and Allergies in Childhood55
3. American Thoracic European Community Respiratory Health Survey56
adolescents (age 11–18 years)
adults (age 19–80 years)
Anxiety and Depression age 10–15 years Children Anxiety and Depression scale57
age >15 years Hospital Anxiety and Depression Scale58
Quality of Life by questionnaire Study 12-item short form (SF-12) to assess health related quality of life55
Study 12-item short form (SF-12)59
Cognitive function by questionnaire
age 15–70 years Perceptual speed intelligence test
age >70 years Mini Mental Status Test (MMST)
Domain boDy
Hand Grip Test60 Hand and forearm muscular strength Trailite, TL-LSC100™
Dual-energy X-ray absorptiometry
DXA®
Fat and lean mass (upper limp, trunk, android, gynoid, lower limp), Bone Mineral Density (lumbar
spine, femur)61
Lunar Prodigy, GE Healthcare®, USA
Activity, diet, nutrition54 Questionnaire
Ever diagnoses of diabetes, osteoporosis, other metabolic diseases Questionnaire
Biobank
Fasting venous blood sample Standard blood chemistry incl. differential, platelet count and Immunoglobulin E. Samplosophy® data matrix sample tube rack system
ISO 9001:2008 certified quality management systemBiobank storage at Biobank Medical University of Vienna 48 µl Frozen Serum, 40 µl Plasma, 20 µl
Urine
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Geographical longitude Geographic latitude NOx 2015 (μg/m³) PM10 2015 (μg/m³)
Vienna AKH 16° 20' 44.0" 48° 13' 10.3" 40,8 20,8
Vienna A23 16° 26' 4.4" 48° 12' 11.0" 64,4 22,9
Vienna Belgradplatz 16° 21' 41.1" 48° 10' 27.7" 51,0 21,3
Vienna Floridsdorf 16° 23' 49.0" 48° 15' 39.9" 42,2 21,1
Vienna Gaudenzdorf 16° 20' 21.6" 48° 11' 13.7" 49,4 21,8
Vienna Hermannskogel 16° 17' 50.1" 48° 16' 12.6" 12,7 -
Vienna Hietzinger Kai 16° 18' 0.1" 48° 11' 18.1" 122,5 -
Vienna Hohe Warte 16° 21' 25.5" 48° 14' 56.4" 31,7 -
Vienna Kaiser-Ebersdorf 16° 28' 33.8" 48° 09' 24.1" 40,0 20,4
Vienna Kendlergasse 16° 18' 35.1" 48° 12' 18.0" 43,1 21,9
Vienna Laaer Berg 16° 23' 34.5" 48° 09' 39.7" 43,1 19,6
Vienna Liesing 16° 18' 4.6" 48° 08' 28.5" 39,7 20,3
Vienna Lobau 16° 31' 32.2" 48° 09' 43.4" 17,0 17,4
Vienna Schafberg 16° 18' 5.6" 48° 14' 7.3" 20,9 18,6
Vienna Stadlau 16° 27' 30.0" 48° 13' 34.9" 42,0 21,4
Vienna Stephansplatz 16° 22' 23.7" 48° 12' 29.3" 36,3 -
Vienna Taborstraße 16° 22' 51.3" 48° 13' 0.3" 65,0 23,0
Figure 3. Monitoring units in Vienna, Austria and average PM 10 and NOX in the year 2015 [Reference from the following source:
City of Vienna, Municipal Department MA 22 - Environmental Protection].
Total Sample
Standard Measurements 
Subgroup classification, if applicable 
Subgroup 1 Subgroup 2
Inclusion criteria
•positive Skin Prick Test or
•prior doctors diagnosed asthma/asthmatic bronchitis or
•prior medical history allergy/ atopy or
•peripheral blood eosinophils >400 cells/μl
Inclusion criteria
•post bronchodilator (FEV1) < LLN or
•FEV1/ VC < 0.7 + age > 18 yrs 
Additional measurements
• bronchial provocation (if no contraindication)
• FeNO
• Asthma Control Test (only prior doctors diagnosed asthma) 
Additional measurements
•six-minute-walk-test 
•rating of perceived exertion scale (BORG Scale)
•COPD Assessment Test 
•Short Form Health Survey (SF-36)
•Self-reported exacerbation
•Modified British Medical Research Council (mMRC)
•α1-antitrypsin quick-screen
Figure 2. Flow chart for additional measurements. FeNO Fractional exhaled Nitric Oxide; FEV1 forced expiratory volume in the
first second; VC Vital capacity; LLN lower limit of normal. References: Six-minute walking test (6MWT)62 expressed as
a percentage of the predicted distance63 and perceived dyspnoea using the modified BORG dyspnoea scale.64 CAT
test; http://www.catestonline.org; 36-item short form (SF-36).65 ACT; https://www.asthmacontroltest.com/.
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errors; (5) study monitoring is performed periodically and
included extensive plausibility checks as well as regular
monitoring reports of the interim data set; and, (6) special
emphasis is placed on quality control of every measurement
report, including a rigorous post hoc quality control of all original
measurements by the steering committee.
External validity
To determine the “representativeness” of the population included
in LEAD compared to the Austrian population, we did extensive
external validity testing. First, we compared LEAD results with
those the most recent Austrian population data published by the
Governmental Statistic Department in 2015.34 Second, the LEAD
study population was compared with the Austrian Governmental
Microcensus in terms of age, gender citizenship, educational
level, and smoking status.35,36 The Microcensus is a randomly
chosen Austrian household’s survey (quarterly sampled), in males
and females aged 15–80 years, depicting socio-demographic
details and, in a subsample, self-reported health status including
smoking status. Due to the compulsory participation (denial
punished by a fee) the Microcensus survey has a very high
response rate (>99%) and high reliability.
Statistical analysis
For this manuscript, continuous data are described using
arithmetic means, standard deviations (SD) and ranges; binary
and ordinal data by frequencies and percentages. In general,
the level of significance (α) was set to 5% (Bonferroni-Holm
correction applied whenever necessary). To analyze external
validity (“representativeness”) α was set to 0.1% (99.9%
confidence intervals) to prevent wrongly significant results for
confidence intervals caused only because of the large sample
sizes. All statistical analyses have been performed using SPSS
24.0 (IBM Corp, Armonk, NY, USA).37
In future analysis of specific LEAD projects we plan to use
knowledge-driven and data-driven (unbiased) analysis, including
principal component analysis, cluster analysis, and network
analysis, to understand the complexity and heterogeneity of the
cohort and different subgroup of participants.22,38,39
RESULTS
Participants’ characteristics
Table 2 presents the major baseline characteristics of the LEAD
study cohort stratified by age. We included 1.344 children age
6 ≤ 18 years (male 54.4%) and 10,079 adults ≥18 years (male
46.65%). Smoking exposure was high since almost one fifth of
children aged 6 ≤ 18 years had been exposed to environmental
tobacco smoke and more than half of the adult participants were
former or current smokers (56%). Former male smokers have
a higher exposure to cigarette smoke compared to current
smokers; therefore, we stratified all smokers using pack years
(PY) showing that 19.5% have or have had a high cigarette
consumption (>20PY). All in all, most participants (86.9%) have
any history of tobacco smoke exposure (passive and=or active).
External validity
Compared to other epidemiological studies,40 the overall response
rate in LEAD was low (total 8.7%, male: 7.7%, female 9.8%). The
low participation rate is probably related to the very rigorous
Austrian data protection law that prohibits iterative invitations
and=or telephone contact. The LEAD study is a single-centered
investigation, with participants having long travel to have
examinations (no monetary incentive). As residential area was
part of the recruitment strategy, a homogenous weighted
proportional population sample of various Viennese districts
had to be guaranteed. When comparing participation rates
between Lower Austria, districts far away and nearby the LEAD
Table 2. Baseline characteristics LEAD study cohort, stratified by age and gender
Children (6–<18 years) Adults (≥18 years)
N = 1,345 N = 10,078
Male Female Male Female
N = 732 N = 613 N = 4,701 N = 5,377
Mean (SD)
(N missing, if any)
Mean (SD)
(N missing, if any)
Mean (SD)
(N missing, if any)
Mean (SD)
(N missing, if any)
Height, cm 152.3 (20.3) 149.6 (15.9) 177.5 (7.1) 164.2 (6.6)
Weight, kg 46.8 (19.3) 44.1 (15.3) 84.5 (14.2) 68.1 (14.0)
BMI, kg=m2 19.3 (4.1) 19.1 (3.9) 26.8 (4.3) 25.3 (5.2)
Waist circumference, cm 69.9 (12.4) (1) 68.3 (10.9) (1) 97.4 (12.7) (6) 88.5 (13.6) (14)
Smoking status
% [CI; 95%]
(N missing, if any)
% [CI; 95%]
(N missing, if any)
% [CI; 95%]
(N missing, if any)
% [CI; 95%]
(N missing, if any)
Never, % 96.6 [95.3–97.9] 97.1 [95.8–98.4] 38.1 [36.7–39.5] 49.1 [47.8–50.4]
Former, % 0.1 [0.0–0.3] 0.2 [0.0–0.6] 35.8 [34.4–37.2] 28.8 [27.6–30.0]
Pack years 22.8 (27.3) (10) 14.5 (18.7) (10)
Current, % 3.3 [2.0–4.6] 2.8 [1.5–4.1] 26.1 [24.8–27.4] 22.0 [20.9–23.1]
Pack years 1.3 (1.5) (2) 0.6 (0.9) 20.0 (21.3) (8) 16.0 (16.0) (10)
Former and currents smokers with <20 pack years, % 3.2 [1.9–4.5] (2) 2.9 [1.6–4.2] 36.8 [35.4–38.2] (18) 36.1 [34.8–37.4] (20)
Former and currents smokers with ≥20 pack years, % none none 25.0 [23.8–26.2] (18) 14.6 [13.7–15.5] (20)
Environmental tobacco smoke (ETS) at most days and=or
nights of week for several hours
In adolescents, % 17.8 [15.0–20.6] (2) 19.7 [16.6–22.8] 38.2 [36.8–39.6] 39.4 [38.1–40.7]
In adulthood, % — — 46.4 [45.0–47.8] (10) 49.5 [48.2–50.8] (7)
BMI, body mass index; CI, confidence interval; SD, standard deviation.
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study center, no difference were found (8.7% vs 6.5% vs 7.1%;
all P-values non-significant). It is known, that participation
rates in health surveys decreased over the past decades,40 and the
considered personal benefit participating in a health survey in
Austria may be low due to the high provision of health care.
Despite this, the external validity (“representativeness”) of the
LEAD cohort is very high. Table 3 shows that the demographic
characteristics of LEAD participants are almost identical to those
of the general Austrian population, stratified by age and gender.
On the other hand, Table 4 compares the sociodemographic data
(citizenship and educational level) of the LEAD cohort (15–80
years) with that of the Austrian Governmental Microcensus
(15–80 years). The LEAD cohort was very similar in terms of
citizenship but not in terms of educational level, which was
shifted towards higher education. Finally, it is important to note
that the smoking history of the LEAD study cohort was well
matched with the results from the Austrian Microcensus both,
in male and female participants (Figure 4).












n % [99.9% CI] % P n % [99.9% CI] % P
6–<10 306 5.6 [4.3–6.9] 4.3 n.s. 233 3.9 [3.0–4.8] 4.1 n.s.
10–<20 546 10.0 [8.6–11.4] 11.8 ≤0.01 522 8.7 [7.4–10.0] 10.8 ≤0.01
20–<30 698 12.8 [11.2–14.4] 15.1 ≤0.01 806 13.5 [12.0–15.0] 14.2 n.s.
30–<40 756 13.9 [12.3–15.5] 15.0 n.s. 784 13.1 [11.6–14.6] 14.5 n.s.
40–<50 885 16.3 [14.5–18.1] 16.7 n.s. 1.077 18.0 [16.3–19.7] 16.5 n.s.
50–<60 877 16.1 [14.4–17.8] 16.8 n.s. 1.034 17.3 [15.6–19.0] 16.7 n.s.
60–<70 810 14.9 [13.2–16.6] 11.5 ≤0.01 967 16.1 [14.4–17.8] 12.4 ≤0.01
≥70 555 10.2 [8.8–11.6] 8.9 n.s. 567 9.5 [8.1–10.9] 10.9 n.s.
CI, confidence interval; n.s., not significant; P, P-value.
Table 4. Sociodemographics of LEAD study cohort compared to
Microcensus
LEAD cohort Austrian Microcensus
n % [99.9% CI] % [99.9% CI] P
Citizenship
Austria 10,099 88.5 [87.5–89.5] 88.6 [87.4–89.8] n.s.
Foreign 1,307 11.5 [10.5–12.5] 11.4 [10.2–12.6] n.s.
Missing 17
Education
LEAD cohort 15–80 years
(n = 10.420)
No education 182 1.7 [1.5–2.0] 1.1 [0.7–1.5] ≤0.01
Primary=lower secondary
education
1,317 12.7 [12.0–13.3] 22.9 [21.3–24.5] ≤0.01
Finished apprenticeship=
vocational training
3,269 31.4 [30.5–32.3] 50.6 [48.7–52.5] ≤0.01
High school 2,769 26.6 [25.8–27.5] 14.0 [12.7–15.3] ≤0.01
University level 2,867 27.6 [26.7–28.4] 11.4 [10.2–12.6] ≤0.01
Missing 16
CI, confidence interval; n.s., not significant; P, P-value.
n.s., not significant.
Figure 4. Smoking status LEAD study cohort compared to microcensus.
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Limitations
1. To obtain all measurements in the entire study population
including valid lung function testing (bodyplethysmography in
particular) for proper comparability throughout age groups, only
participants ≥6 years could be included. In addition, radiation
exposure by dual-energy X-ray absorptiometry is prohibited in
those <6 years of age. Therefore, first infant years of lung
function development will not be available in this study.
2. Information on individual’s early life exposure like birth
history, childhood respiratory infections, diagnoses, and maternal=
paternal data on occupational exposure, migration, life style, and
smoking behavior are documented only via questionnaires and
retrospectively in those <18 years. The validity is demonstrated
by the accompanying parents at the study visit. In those >18 years
this information may be lacking due to individual’s memory (gap)
or nescience.
3. The LEAD cohort shows higher education levels compared
to the general Austrian population. This is a well-known
challenge within populational based studies based on voluntary
participation.41 Education is a well described and recognized
factor on lung function, in both childhood and adulthood.42 This
weakness is addressed as a major limitation within the LEAD
cohort. To at least reduce this effect the authors will define
recommended individual’s (for adults) and mothers=fathers (for
children) socioeconomic status, including education, occupation,
and income.43
DISCUSSION
The ongoing LEAD study includes a large and carefully
characterized cohort representative for the general population of
Austria with respect to age, gender, and smoking status. The high
quality of the dataset is guaranteed by the protocol based standard
measurements, the trained personnel and interview based
questionnaires obtained in all participants, through the direct
data transfer from the equipment into the study specific tailored
web tool preventing manual data input errors, and through regular
study monitoring reports, interim data sets, and plausibility
checks. In addition, rigorous post hoc quality control of every
single measurement report is done by the steering committee.
The representativeness of the LEAD study cohort is supported
by the comparison with the governmental data of the Austrian
population that shows almost identical distribution of age, gender
and citizenship. The shift towards higher education levels in the
LEAD study cohort is also seen in other epidemiological studies,
and is likely due to an increased health awareness of higher
educated participants.44
The LEAD study has some clear strengths: (1) to our
knowledge, it is among the biggest longitudinal population-based
cohort studies providing pre- and post-bronchodilation spirometry
and body plethysmography and diffusing capacity results to better
characterize chronic respiratory disease as recommended by the
European Respiratory Society45; (2) to validate prospectively
lung function trajectories from infancy to late adulthood,4 the
LEAD cohort included participants from 6 to 80 years, and most
of the risk factors recently discussed13,46,47 have been considered
in the analysis; (3) to study the impact of environmental factors
on lung function, data from seventeen environmental monitoring
units in Vienna calculate the average concentrations of particulate
matter 10 (PM10) and Nitrogen oxide (NOX) within 10m3 of
every participant’s home and work place address using the
emission and combustion model48; (4) to cover risk factors based
on symptoms, socioeconomic status, smoking status, and self-
rated general health, a LEAD study cohort tailored questionnaire
was generated for different age groups based on validated
questionnaires (for detailed information see Table 2). In addition,
anxiety and depression, quality of life, and cognitive function
were also evaluated; (5) to minimize recall bias for undiagnosed
or self-reported coexisting diseases, the LEAD study measures
key organ function data to screen for cardiovascular, metabolic,
and body composition data for muscle=fat distribution as well as
for osteoporosis and screening test for cognitive function. This
approach provides a framework for the exploration of the
relationships between lung health, age, and multi-morbidity in a
broader context; and, finally, (6) LEAD has created a blood=urine
biobank, hosted by the Medical University of Vienna, which is
open to future international collaborations to better understand
genetic risk factors and biomarkers influencing lung function
development and decline.
In summary, the LEAD cohort has been established following
high quality standards; it is representative of the Austrian
population and offers a platform to understand lung development
and ageing as a key mechanism of human health both, in early
and late adulthood.
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